- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03767777
Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY(PATENCY)
Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY:A Prospective, Multi-center, Objective Performance Criteria Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This clinical trial was conducted in a qualified clinical trial institution. Investigators will use Artery Stent Graft System manufactured by Lifetech Scientific (Shenzhen) Co., LTD. to treat patients with thoracic aortic dissection involving the aortic arch. This is a Prospective, Multi-center, Objective Performance Criteria Clinical Trial. It is expected to submit to the ethics committee of the lead unit for review in Sep 2018, and complete the implantation of 150 patients in 18 centres nationwide within 12 months, and interim follow-up was conducted before discharge, 30 days after surgery, 6 months after surgery and 12 months after surgery, long-term follow-up will be performed at 24 months postoperatively, 36 months postoperatively, 48 months postoperatively and 60 months postoperatively.
This trial will evaluate whether the device reached the primary safety endpoint and primary efficacy endpoint through two primary endpoint indicators: the incidence of major adverse events (MAE) within 30 days and the success rate of aortic dissection treatment 12 months after surgery.
This trail will evaluate whether the device reached the secondary safety endpoint and efficacy endpoint through several secondary endpoint indicators:
- the incidence of all-cause death at 30 days, 6 months, 12 months and 2-5 years after surgery
- the incidence of thoracic aortic dissection-related death at 30 days, 6 months, 12 months and 2-5 years after surgery
- the incidence of severe adverse events (SAE) at 30 days, 6 months, 12 months and 2-5 years after surgery
- the incidence of the device-related adverse events (AE) at 30 days, 6 months, 12 months and 2-5 years after surgery
- the Incidence of left upper limb ischemia at 30 days, 6 months, 12 months and 2-5 years after surgery
- the incidence of type I or type III leakage at 30 days, 6 months, 12 months after surgery
- the incidence of graft migration at 30 days, 6 months, 12 months after surgery
- the branching vascular patency rate at 30 days, 6 months, 12 months after surgery
- the Incidence of Thoracic aortic dissection -related surgical conversion or re-intervention at 30 days, 6 months, 12 months and 2-5 years after surgery According to the guidelines for clinical trials of aortic stent system, the sponsor will apply for NMPA listing registration after completing a 12-month primary endpoint assessment, and annually follow-up will be conducted until the fifth year for the long-term efficacy observation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Chinese PLA General Hospita
-
Beijing, Beijing, China, 100037
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
-
Gansu
-
Lanzhou, Gansu, China
- The Frist Hospital of Lanzhou University
-
-
Guangxi
-
Liuzhou, Guangxi, China
- LIU ZHOU WORKER'S HOSPITAL,Fourth Affiliated Hospital of Guangxi Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- The Second Affiliated Hospital of Harbin Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Provincial People's Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- The Central Hospital of Wuhan
-
Wuhan, Hubei, China
- Tongji Hospital,Tongji Medical College of Huazhong University of Science&Technology
-
-
Hunan
-
Changsha, Hunan, China
- The Second Xiangya Hospital Of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Nanjing Drum Tower Hospital (Nanjing Gulou Yi Yuan), the Affiliated Hospital of Nanjing University Medical School
-
Suzhou, Jiangsu, China
- The First Affiliated Hospital of Soochow University
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- The Second Affiliated Hospital of Nanchang University
-
-
Jilin
-
Chang chun, Jilin, China
- The First Hospital of Jilin University
-
-
Shandong
-
Jinan, Shandong, China
- Shandong Provincial Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai, Shanghai, China
- Zhongshan Hospital, Fudan University
-
-
Shanxi
-
Xi'an, Shanxi, China
- Xijing Hospital, the Fourth Military Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China Hospital of Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China
- Tianjing Medical University General Hospital
-
Tianjin, Tianjin, China
- Tianjin Chest Hospital
-
-
Yunnan
-
Kunming, Yunnan, China
- The First People's Hospital of Yunnan Province
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients are 18 years and older, but less than 85 years old and not pregnant or lactating;
- Patients who can understand the purpose of the trial, voluntarily participate in and sign the informed consent, and are willing to complete the follow-up according to the requirements of the protocol;
- Patients diagnosed as thoracic aortic dissection involving the arch, and the left subclavian artery branching vessel needs to be revascularized;
- Aortic proximal landing zone ≥15mm;
- Aortic proximal diameter in the range of 25-44mm;
- The left subclavian artery distal landing zone≥15mm;
- The left subclavian artery diameter in the range of 5-18mm;
- Patients who have eligible imported arterial vessels.
Exclusion Criteria:
- Patients with severe stenosis, calcification in the landing area of the stent and easily lead to incomplete stent apposition;
- Patients need intervention for other vascular diseases (such as coronary artery /renal artery) in the same surgery, or patients with heart disease and medicine treatment will be affected by the intervention;
- Patients with a history of myocardial infraction or acute coronary syndromes in 3 months;
- Patients with a history of cerebrovascular events or gastrointestinal bleeding in 3 months, antiplatelet agent and anticoagulant contraindication, or tendency of hemorrhage;
- Patients have received any major surgical or interventional therapy within 30 days (Operation Classification reaches III or above) or have received interventional therapy;
- Patients will receive any major selective operation or interventional therapy in 30days (Operation Classification reaches III or above) or will received interventional therapy;
- Patients already treated with an thoracic aortic stent graft and the stent graft can affect operation or intersection part existing between the graft covering area;
- Patients with genetic connective tissue disease (e.g., Marfans syndrome) or aorta hereditary disease;
- Patients with infectious aortic dissection;
- Patients with acute systemic infection;
- Patients with major organ failure or other serious diseases;
- Patients with a history of active bleeding, clotting disorder, or rejection of blood transfusions;
- Patients with liver dysfunction: preoperative creatinine was 2.5 times higher than the normal upper limit; Alanine transaminase (ALT) or Aspartate transaminase (AST) were 5 times higher than the normal upper limit; serum total bilirubin (STB) was 2 times higher than the normal upper limit;
- Pregnant or lactating women or women who plan to get pregnant;
- Patients who can not tolerate to Anaesthetic;
- Patients with a history of allergy to contrast media, stents and conveyor materials (including nickel and titanium, polyester, PTFE, and nylon polymer materials);
- Patients with a life expectancy less than 12 months(such as terminal malignant tumor);
- Patients who were not suitable for endovascular treatment, judged by the investigator;
- Patients who participated in clinical trials of other drugs or medical devices at the same time.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Participants will be treated with Artery Stent Graft System Intervention: Device: Artery Stent Graft System
|
The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system.
During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The treatment success rate of aortic dissection at 12 months post-implant
Time Frame: 12 months after surgery
|
Assessment of the rate of successful disease treatment defined as immediate technical success and freedom from secondary intervention at 12 months of follow-up. Technique success means delivery system is successfully transported to the predetermined position, both of aorta stent graft and aortic branch stent graft successfully expanded and delivery system withdraw successfully.No type I/III endoleak at the end of operation, no conversion to open surgery. (Adjuvant Interventions during operation do not defined as technical failure.) |
12 months after surgery
|
Incidence of no major adverse events (MAE) occurred at 30 days post-implant
Time Frame: 30 days after surgery
|
Major Adverse events (MAE) are defined as aortic dissection related mortality, ischemic stroke, and paraplegia.
|
30 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of all-cause death
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Incidence of Aortic dissection dissection-related death
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Incidence of Serious Major Adverse Event(SAE)
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Incidence of device related adverse events(AE)
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Incidence of left upper limb ischemia
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Incidence of I/III type endoleaks
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Incidence of graft migration
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Branching vascular patency rate
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Incidence of Thoracic aortic dissection -related surgical conversion or re-intervention
Time Frame: 30 days,6 months, 12 months and 2-5 years after surgery
|
30 days,6 months, 12 months and 2-5 years after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chang Shu, professor, Central South University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LTP84-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracic Aortic Dissection
-
University of PennsylvaniaBolton MedicalEnrolling by invitationThoracic Aortic Aneurysm | Thoracic Aortic Dissection | MicroemboliUnited States
-
Petrovsky National Research Centre of SurgeryRecruitingThoracic Aortic Aneurysm | Thoracic Aortic Dissection | Cardiac Valve Disease | Aortic Aneurysm and DissectionRussian Federation
-
Rodney A. White, M.D.CompletedThoracic Aortic Dissection | Intramural Hematoma | Thoracic Aortic Aneurysms | Pseudoaneurysm | Thoracic TransectionsUnited States
-
Vascutek Ltd.Bolton MedicalRecruitingThoracic Diseases | Aortic Aneurysm | Aortic Dissection | Thoracic Aortic Aneurysm | Thoracic Aortic DissectionUnited States, Germany
-
Assiut UniversityRecruitingAortic Root Aneurysm | Aortic Root DissectionEgypt
-
Braile Biomedica Ind. Com. e Repr. Ltda.RecruitingThoracic Aortic DissectionBrazil
-
The University of Texas Health Science Center,...Washington University School of Medicine; University of Michigan; John Ritter...Active, not recruiting
-
W.L.Gore & AssociatesCompletedThoracic Aortic Aneurysm | Thoracic Aortic Dissection | Thoracic Aorta Injury
-
University Hospital, Basel, SwitzerlandRecruitingThoracic Aortic Aneurysm | Acute Aortic DissectionSwitzerland
-
W.L.Gore & AssociatesCompletedAortic Diseases | Aortic Aneurysm, Thoracic | Penetrating Ulcer | Descending Thoracic Aortic Dissection | Aorta Thoracic; Traumatic RuptureFrance
Clinical Trials on Artery Stent Graft System
-
EndologixPQ Bypass, Inc.; SyntactxActive, not recruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingAbdominal Aortic AneurysmTurkey, Bulgaria, Greece
-
Terumo CVSVascutek Ltd.CompletedInfrarenal Abdominal Aortic AneurysmCanada, United States
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Bolton MedicalActive, not recruitingAortic Dissection Type BUnited States
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmUnited States
-
Xijing HospitalChanghai HospitalUnknown
-
Dr. Sabrina OverhagenActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm, Without Mention of RuptureGermany
-
EndologixCompleted
-
Xijing HospitalChanghai Hospital; Shanghai Zhongshan HospitalUnknown